Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03539549 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT03539549 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 124 participants.
The verdict
NCT03539549, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate abicipar pegol for safety and treatment effects in participants with neovascular age-related macular degeneration (AMD).
Interventions
- DRUG Abicipar pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2018-05-25 |
| Est. Completion | 2019-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03539549
The ClinicalTrials.gov registry entry for NCT03539549 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abicipar pegol is the first listed.
NCT03539549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03539549 about?
NCT03539549 is a clinical study titled "A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)". The objective of this study is to evaluate abicipar pegol for safety and treatment effects in participants with neovascular age-related macular degeneration (AMD).
What is the current status of trial NCT03539549?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2018-05-25. Estimated completion is 2019-02-27.
What interventions are being tested in trial NCT03539549?
The interventions under investigation include: Abicipar pegol (DRUG).
Who is sponsoring clinical trial NCT03539549?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.